GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stereotaxis Inc (FRA:RJR1) » Definitions » ROCE %

Stereotaxis (FRA:RJR1) ROCE % : -113.78% (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Stereotaxis ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Stereotaxis's annualized ROCE % for the quarter that ended in Dec. 2024 was -113.78%.


Stereotaxis ROCE % Historical Data

The historical data trend for Stereotaxis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stereotaxis ROCE % Chart

Stereotaxis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.60 -29.76 -44.78 -63.36 -93.99

Stereotaxis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.74 -68.82 -96.14 -92.78 -113.78

Stereotaxis ROCE % Calculation

Stereotaxis's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-23.626/( ( (38.431 - 12.147) + (44.621 - 20.63) )/ 2 )
=-23.626/( (26.284+23.991)/ 2 )
=-23.626/25.1375
=-93.99 %

Stereotaxis's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=-29.136/( ( (45.892 - 18.67) + (44.621 - 20.63) )/ 2 )
=-29.136/( ( 27.222 + 23.991 )/ 2 )
=-29.136/25.6065
=-113.78 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stereotaxis  (FRA:RJR1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Stereotaxis ROCE % Related Terms

Thank you for viewing the detailed overview of Stereotaxis's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stereotaxis Business Description

Traded in Other Exchanges
Address
710 North Tucker Boulevard, Suite 110, St. Louis, MO, USA, 63101
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Stereotaxis Headlines

No Headlines